This morning, Reunion Neuroscience shared positive topline data from its Phase 2 trial of RE104 in postpartum depression (PPD), a study that saw 84 female patients with moderate to severe PPD enrolled across 38 U.S. sites (NCT06342310; ‘RECONNECT’). RE104, the company’s lead candidate, is a prodrug of 4-OH-DiPT, one of Sasha Shulgin’s TiHKAL compounds. With a duration of several hours…
